Cargando…
A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer that lacks an estrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2 (HER2), making it unsuitable for hormonal- or HER2-based therapy. TNBC is known...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074041/ https://www.ncbi.nlm.nih.gov/pubmed/33919653 http://dx.doi.org/10.3390/cancers13081954 |
_version_ | 1783684266005102592 |
---|---|
author | Tukaramrao, Diwakar Bastihalli Malla, Saloni Saraiya, Siddharth Hanely, Ross Allen Ray, Aniruddha Kumari, Shikha Raman, Dayanidhi Tiwari, Amit K. |
author_facet | Tukaramrao, Diwakar Bastihalli Malla, Saloni Saraiya, Siddharth Hanely, Ross Allen Ray, Aniruddha Kumari, Shikha Raman, Dayanidhi Tiwari, Amit K. |
author_sort | Tukaramrao, Diwakar Bastihalli |
collection | PubMed |
description | SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer that lacks an estrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2 (HER2), making it unsuitable for hormonal- or HER2-based therapy. TNBC is known for its higher relapse rate, poorer prognosis and higher rate of metastasis compared to non-TNBC because although patients initially respond to chemotherapy that kills cancer cells through a form of programmed cell death called apoptosis, they later develop chemoresistance and stop responding to the treatment, accounting for one fourth of all breast cancer deaths. In this study, we report a novel compound, TPH104, that elicits a unique, non-apoptotic cell death in TNBC cells. Upon treatment with TPH104, TNBC cells swell and burst, releasing immunogenic markers that alert and activate the immune system to further recognize and attack the neighboring breast cancer cells. ABSTRACT: Enhancing the tumor immunogenic microenvironment has been suggested to circumvent triple-negative breast cancer (TNBC) resistance and increase the efficacy of conventional chemotherapy. Here, we report a novel chemotherapeutic compound, TPH104, which induces immunogenic cell death in the TNBC cell line MDA-MB-231, by increasing the stimulatory capacity of dendritic cells (DCs), with an IC(50) value of 140 nM. TPH104 (5 µM) significantly increased ATP levels in the supernatant and mobilized intracellular calreticulin to the plasma membrane in MDA-MB-231 cells, compared to cells incubated with the vehicle. Incubating MDA-MB-231 cells for 12 h with TPH104 (1–5 µM) significantly increased TNF-α mRNA levels. The supernatants of dying MDAMB-231 cells incubated with TPH104 increased mouse bone marrow-derived DC maturation, the expression of MHC-II and CD86 and the mRNA expression of TNF-α, IL-6 and IL-12. Overall, these results indicate that TPH104 induces immunogenic cell death in TNBC cells, in part, by activating DCs. |
format | Online Article Text |
id | pubmed-8074041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80740412021-04-27 A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells Tukaramrao, Diwakar Bastihalli Malla, Saloni Saraiya, Siddharth Hanely, Ross Allen Ray, Aniruddha Kumari, Shikha Raman, Dayanidhi Tiwari, Amit K. Cancers (Basel) Article SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer that lacks an estrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2 (HER2), making it unsuitable for hormonal- or HER2-based therapy. TNBC is known for its higher relapse rate, poorer prognosis and higher rate of metastasis compared to non-TNBC because although patients initially respond to chemotherapy that kills cancer cells through a form of programmed cell death called apoptosis, they later develop chemoresistance and stop responding to the treatment, accounting for one fourth of all breast cancer deaths. In this study, we report a novel compound, TPH104, that elicits a unique, non-apoptotic cell death in TNBC cells. Upon treatment with TPH104, TNBC cells swell and burst, releasing immunogenic markers that alert and activate the immune system to further recognize and attack the neighboring breast cancer cells. ABSTRACT: Enhancing the tumor immunogenic microenvironment has been suggested to circumvent triple-negative breast cancer (TNBC) resistance and increase the efficacy of conventional chemotherapy. Here, we report a novel chemotherapeutic compound, TPH104, which induces immunogenic cell death in the TNBC cell line MDA-MB-231, by increasing the stimulatory capacity of dendritic cells (DCs), with an IC(50) value of 140 nM. TPH104 (5 µM) significantly increased ATP levels in the supernatant and mobilized intracellular calreticulin to the plasma membrane in MDA-MB-231 cells, compared to cells incubated with the vehicle. Incubating MDA-MB-231 cells for 12 h with TPH104 (1–5 µM) significantly increased TNF-α mRNA levels. The supernatants of dying MDAMB-231 cells incubated with TPH104 increased mouse bone marrow-derived DC maturation, the expression of MHC-II and CD86 and the mRNA expression of TNF-α, IL-6 and IL-12. Overall, these results indicate that TPH104 induces immunogenic cell death in TNBC cells, in part, by activating DCs. MDPI 2021-04-18 /pmc/articles/PMC8074041/ /pubmed/33919653 http://dx.doi.org/10.3390/cancers13081954 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tukaramrao, Diwakar Bastihalli Malla, Saloni Saraiya, Siddharth Hanely, Ross Allen Ray, Aniruddha Kumari, Shikha Raman, Dayanidhi Tiwari, Amit K. A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells |
title | A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells |
title_full | A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells |
title_fullStr | A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells |
title_full_unstemmed | A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells |
title_short | A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells |
title_sort | novel thienopyrimidine analog, tph104, mediates immunogenic cell death in triple-negative breast cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074041/ https://www.ncbi.nlm.nih.gov/pubmed/33919653 http://dx.doi.org/10.3390/cancers13081954 |
work_keys_str_mv | AT tukaramraodiwakarbastihalli anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT mallasaloni anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT saraiyasiddharth anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT hanelyrossallen anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT rayaniruddha anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT kumarishikha anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT ramandayanidhi anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT tiwariamitk anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT tukaramraodiwakarbastihalli novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT mallasaloni novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT saraiyasiddharth novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT hanelyrossallen novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT rayaniruddha novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT kumarishikha novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT ramandayanidhi novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells AT tiwariamitk novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells |